Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Meropenem stands out as an antibiotic to be used first in ESBL and MDR infections, given its efficacy profile and safety record (see earlier blog). It also would seem to be appropriate to use relatively high doses or prolonged infusion times – or both – to improve T>MIC for the Continue reading To Kill A Mocking Bug – of the CRKP or CRAB Variety
During the past few weeks the case of a patient with MDR Klebsiella infection has made the news. We are told that this particular pathogen is “resistant to 26 antibiotics”. We were informed that the patient had multiple prior hospitalizations in India, supposedly the origin of the uncontrolled untreatable infection. Continue reading CDC Report on Pan-Resistant NDM Klebsiella in Nevada– A Sad Tale
Just before the November 4th AMDAC on solithromycin, we are being treated to a very fine piece of study write-up. Of course, we are speaking of the File paper on the SOLITAIRE-IV trial, and what a fine piece of crafty penmanship it is, if you haven’t noticed. Just as a Continue reading Solithromycin SOLITAIRE-IV: So-So Results for a So-So Drug